CJC-1295 No DAC Dosing Guide

CJC-1295 No DAC Quick Start

CJC-1295 No DAC, also called Modified GRF 1-29 or Mod GRF 1-29, is a short-acting copy of the body's own growth-hormone-releasing hormone (GHRH). It tells the pituitary gland to release a short burst of growth hormone, then clears the body in about 30 minutes.

Researchers planning protocols usually pair it with Ipamorelin because the two compounds push the pituitary through different doors at the same time. CJC-1295 No DAC is not FDA-approved and is used only in research-reference contexts.

Half-life

About 30 minutes. Each dose creates one short pulse, then fades.

Common dose range

100–300 mcg per injection, 1–3 times daily in fasted windows.

Default vial setup

10 mg vial with 3 mL bacteriostatic water gives a clean 3,333 mcg/mL working solution.

Route

Subcutaneous (SubQ) with a U-100 insulin syringe.

Status

Not FDA-approved. Educational research reference only.

Disclaimer

This page is an educational research reference and is not medical advice or a treatment plan. CJC-1295 No DAC is not approved by the FDA for human use.

This no-DAC page covers dose timing and setup. Want the bigger CJC view? See the CJC-1295 research overview. It covers effects, studies, safety notes, and legal status.

CJC-1295 No DAC Dosing Protocol & Schedule

Most CJC-1295 No DAC research protocols start low and increase slowly. The short half-life means each dose is mostly independent, so timing the dose around fasted windows usually matters more than chasing a higher number.

Typical Titration Pattern

Common CJC-1295 No DAC titration framework

Phase

Initiation

Window

Weeks 1–2

Dose per injection

100 mcg, once daily

Notes

Pre-bed in a fasted window. Used to check tolerance.

Early escalation

Weeks 3–4

150 mcg, once daily

Increase by 50 mcg only if initiation is tolerated.

Therapeutic range

Weeks 5–8

200 mcg, once daily

Common maintenance level in community protocols.

Advanced range

Weeks 5–12+

200–300 mcg, 1–2x daily

Often split between morning fasted and pre-bed windows.

Upper community range

Protocol-dependent

Up to 300 mcg, up to 3x daily

Higher single doses tend to add side effects without bigger GH gains.

Initiation

Weeks 1–2

100 mcg, once daily

Pre-bed in a fasted window. Used to check tolerance.

Early escalation

Weeks 3–4

150 mcg, once daily

Increase by 50 mcg only if initiation is tolerated.

Therapeutic range

Weeks 5–8

200 mcg, once daily

Common maintenance level in community protocols.

Advanced range

Weeks 5–12+

200–300 mcg, 1–2x daily

Often split between morning fasted and pre-bed windows.

Upper community range

Protocol-dependent

Up to 300 mcg, up to 3x daily

Higher single doses tend to add side effects without bigger GH gains.

Not a dosing recommendation. This is a summary of community protocol structure used for research planning.

Why Frequency Often Beats a Higher Single Dose

Researchers describe a saturation point: roughly 100 mcg seems to fill the available pituitary receptors for a single pulse. Pushing past that with a larger single dose does not usually create a much larger growth hormone burst. That is why most planning frameworks add a second daily injection before they raise the size of one dose.

Timing Rules That Show Up in Most Protocols

Most protocols describe dosing in a fasted window. Food, especially carbs, can dampen the GH pulse because insulin blunts GH signaling.

A common rule is at least 2 hours after eating and 30 minutes before eating again.

Pre-bed dosing lines up with the body's largest natural GH pulse during deep sleep.

Community protocols describe skipping a missed dose rather than doubling up the next day, citing the short half-life.

Many planning frameworks use 5-days-on / 2-days-off, or 8–12 week cycles followed by 4–6 weeks off, to manage receptor sensitivity.

Cycle Guidelines

Cycle length patterns in community planning

Approach

Short cycle

Length

4–6 weeks

Off period

2–4 weeks

Common use

Test tolerance and response.

Standard cycle

8–12 weeks

Most common maintenance pattern.

Pulsed week

5 days on / 2 days off

Built into cycle

Used to keep pituitary receptors responsive.

Short cycle

4–6 weeks

2–4 weeks

Test tolerance and response.

Standard cycle

8–12 weeks

Most common maintenance pattern.

Pulsed week

5 days on / 2 days off

Built into cycle

Used to keep pituitary receptors responsive.

These cycle structures come from community-derived planning. No randomized trial defines an ideal cycle length for the No DAC variant.

Evidence boundary

No published human trial has tested the No DAC variant directly at protocol scale. These dosing patterns are extrapolated from parent CJC-1295 research, GHRH pharmacology, and community use.

CJC-1295 No DAC Supplies Needed

These supplies are planned around the 10 mg vial / 3 mL BAC water default and a daily injection schedule.

Recommended USA Supply

Use discount code SAVE10 at Peptira checkout. See why we love Peptira.

Ipamorelin + CJC Blend

At-Home Blood Test

Research Supplies

U-100 insulin syringes.

Sterile alcohol prep pads.

For home or car.

Travel case.

Cooled travel case.

Disclosure: supply links may earn PDP a commission at no cost to you.

Peptide Vials (10 mg default)

At 200 mcg per daily injection, one 10 mg vial covers roughly 50 doses. At 100 mcg per dose it covers up to 100 doses. Once daily dosing is used in this plan.

4-6 weeks

1 vial

4 weeks: 28 daily injections; one 10 mg vial covers the cycle.; 6 weeks: 42 daily injections; still within one 10 mg vial.

8-12 weeks

2 vials

8 weeks: 56 daily injections; one vial covers 50 doses, second vial gives margin.; 12 weeks: 84 daily injections; two vials cover 100 doses.

4 weeks: 28 daily injections; one 10 mg vial covers the cycle.; 6 weeks: 42 daily injections; still within one 10 mg vial.

8 weeks: 56 daily injections; one vial covers 50 doses, second vial gives margin.; 12 weeks: 84 daily injections; two vials cover 100 doses.

Insulin Syringes (U-100, 0.3 mL / 30-unit)

Smaller barrels make it easier to read low unit counts like 3 or 6 units at the 10 mg / 3 mL default.

4 weeks

28 syringes

One syringe per injection.

6 weeks

42 syringes

8 weeks

56 syringes

12 weeks

84 syringes

One syringe per injection.

Bacteriostatic Water

Each 10 mg vial uses 3 mL BAC water. A 10 mL bottle covers about 3 vials with margin.

4-12 weeks

1 x 10 mL bottle

4 weeks: 3 mL used; bottle has plenty of margin.; 8 weeks: 6 mL used across 2 vials; still within one bottle.; 12 weeks: 6–9 mL used across 2 vials; one bottle covers margin.

4 weeks: 3 mL used; bottle has plenty of margin.; 8 weeks: 6 mL used across 2 vials; still within one bottle.; 12 weeks: 6–9 mL used across 2 vials; one bottle covers margin.

Round up for priming losses, dropped syringes, and protocol adjustments. For split 1-2x daily dosing schedules, double the syringe and swab counts.

Companion Supplies & Routine Support

Research setup8

Tracking & organization2

Skin routine9

GLP-1 & digestive support3

Vitamins & minerals7

Protein, creatine & metabolic4

CJC-1295 No DAC Reconstitution Guide

The default setup on this page is the 10 mg vial with 3 mL bacteriostatic water. That gives a working solution of about 3,333 mcg/mL, which makes the most common research doses snap to clean unit numbers on a U-100 insulin syringe.

Default: 10 mg Vial + 3 mL BAC Water

10 mg / 3 mL setup → 3,333 mcg/mL. Units shown for a U-100 syringe.

Target dose

100 mcg

Volume to draw

0.03 mL

U-100 syringe units

3 units

150 mcg

0.045 mL

~4.5 units

200 mcg

0.06 mL

6 units

300 mcg

0.09 mL

9 units

100 mcg

0.03 mL

3 units

150 mcg

0.045 mL

~4.5 units

200 mcg

0.06 mL

6 units

300 mcg

0.09 mL

9 units

Use a 0.3 mL / 30-unit syringe for easier reading at these small volumes.

Other Common Vial / BAC Water Combinations

Reconstitution reference for other common formats

Vial

2 mg

BAC water

1.0 mL

Concentration

2,000 mcg/mL

5 units

10 units

15 units

2.0 mL

1,000 mcg/mL

20 units

30 units

5 mg

2,500 mcg/mL

4 units

8 units

12 units

3.0 mL

1,667 mcg/mL

18 units

5.0 mL

10 mg

3,333 mcg/mL

2 mg

1.0 mL

2,000 mcg/mL

5 units

10 units

15 units

2.0 mL

1,000 mcg/mL

20 units

30 units

5 mg

2,500 mcg/mL

4 units

8 units

12 units

3.0 mL

1,667 mcg/mL

18 units

5.0 mL

10 mg

3,333 mcg/mL

Pick a setup where your most common dose lands on a whole or half unit so it is easy to draw.

Step-By-Step Reconstitution

Gather supplies

CJC-1295 No DAC vial, bacteriostatic water, alcohol swabs, and a U-100 insulin syringe.

Clean both stoppers

Wipe the peptide vial stopper and the BAC water vial stopper with separate alcohol swabs. Let them air dry.

Draw the BAC water

Draw the planned BAC water volume (3 mL for the default 10 mg setup) into a syringe.

Add the water slowly

Inject the BAC water slowly down the inside wall of the peptide vial. Do not aim the stream at the powder.

Mix gently

Roll or gently swirl the vial. Do not shake. Shaking can damage the peptide.

Inspect the solution

The liquid should be clear and free of visible particles. Discard the vial if it is cloudy or discolored.

Label and store

Write the concentration and reconstitution date on the vial. Refrigerate at 2–8°C (36–46°F) and use within about 2–4 weeks.

Need a custom setup?

Use the PepPal reconstitution calculator to plug in any vial size and BAC water volume and get exact unit counts.

CJC-1295 No DAC Dosage Chart

This CJC-1295 No DAC dosage chart summarizes a common daily titration schedule from 100 mcg up to 200 mcg, with optional advanced dosing shown by week range.

How CJC-1295 No DAC Works

CJC-1295 No DAC is a small change to the body's own growth-hormone-releasing hormone (GHRH). Four edits to the sequence make it last longer than natural GHRH, which only survives a few minutes. The change gives it a half-life of about 30 minutes.

Step One: It Attaches to GHRH Receptors

Once injected, CJC-1295 No DAC travels to the pituitary gland — a small structure at the base of the brain that controls many hormones. It attaches to GHRH receptors on the pituitary and tells the gland to release growth hormone (GH).

Step Two: A Short, Clean GH Pulse

Because the compound clears in about 30 minutes, each dose makes one short GH burst, then fades. That pulsatile pattern is closer to how the body normally releases GH in waves, especially during deep sleep. Many planning frameworks favor it over long-acting compounds because the pulse-and-rest pattern may help keep receptors responsive over time.

Step Three: GH Tells the Liver to Make IGF-1

Each GH pulse signals the liver to produce IGF-1 (insulin-like growth factor 1). IGF-1 is one of the markers researchers track because it carries many of the downstream effects on tissue, muscle, and metabolism.

Why Ipamorelin Often Comes Along

Ipamorelin is a different kind of GH stimulator. It works through the ghrelin receptor, not the GHRH receptor. Pushing both doors at once usually creates a larger GH pulse than either compound alone. That is why CJC-1295 No DAC + Ipamorelin is one of the most discussed GH-related stack patterns in research planning.

Pulsatile signal

Short half-life supports clean, separated GH pulses rather than constant elevation.

GHRH receptor only

Selective for GHRH receptors. Does not directly activate the ghrelin pathway.

Downstream IGF-1

Repeated daily pulses can hold IGF-1 levels higher over time even when each single dose washes out quickly.

Empty-stomach effect

Insulin from a recent meal can blunt the GH pulse, which is why fasted windows are common in planning.

Who CJC-1295 No DAC Is For and Who Should Avoid It

This page is a research-planning reference. The note below covers who research protocols typically exclude, not who can or cannot use the compound personally. There is no human-use approval, and the decision should always involve a licensed clinician.

Groups Most Protocols Exclude

Active cancer or recent cancer history. GH and IGF-1 can affect cell growth, and most planning frameworks exclude this group by default.

Meaningful cardiovascular disease, especially uncontrolled heart conditions.

Pregnancy or breastfeeding.

Significant glucose dysregulation or uncontrolled diabetes, because GH can raise blood sugar.

Known hypersensitivity to peptide products or to bacteriostatic water (benzyl alcohol).

Medication Conflicts to Flag

Glucocorticoids (steroids) can blunt GH response and may complicate planning.

Insulin and oral diabetes medications may interact with GH-driven glucose changes.

Thyroid medication adjustments may be relevant because GH affects thyroid hormone conversion.

Clinical oversight

Anything in this section is general research-planning context. Decisions about who should or should not consider any peptide protocol should be made with a licensed clinician who can review individual medical history, labs, and medications.

CJC-1295 No DAC Side Effects & Safety

CJC-1295 No DAC is often described as easier to titrate than the DAC version because side effects fade with the compound itself. Most reported effects pass within 30–60 minutes of a dose.

Commonly Reported Effects

Mild flushing or warmth shortly after the injection.

Headache, usually mild and short-lived.

Injection-site redness or irritation.

Mild water retention or puffiness.

Tingling or numbness in the hands, sometimes linked to higher single doses.

Dose-Dependent Pattern

Higher single doses tend to produce more flushing and headache without a proportional GH gain. This is part of why most planning frameworks add a second daily dose before they raise the size of a single dose.

Theoretical Long-Term Concerns

Long-term effects on insulin sensitivity and blood sugar are not well studied for the No DAC variant.

Long-term IGF-1 elevation has theoretical implications for cell growth, which is one reason cancer history is treated as an exclusion.

No multi-year human safety data exists for the No DAC version specifically.

The CJC-1295 with DAC Safety Event

A 2006 Phase 2 trial of CJC-1295 with DAC in HIV patients was halted after a participant had a heart attack. Investigators later said the event was unrelated to the compound, but the program was discontinued. That event is tied to the DAC version, which keeps GH levels elevated for days. No similar signal has been reported for the No DAC variant.

Quality-Control Risk

Because CJC-1295 No DAC is sold as a research compound, purity and identity vary by supplier. Match the certificate of analysis (COA) to the exact product and batch where possible. PepPal tracks COA depth and independent testing on its supplier comparison pages.

CJC-1295 No DAC Timeline & What to Monitor

There is no large outcome trial that maps response timelines for the No DAC variant. The general timing markers below come from parent-compound research, GH/IGF-1 physiology, and community planning.

General timing markers used in planning

Per-dose (0–60 min)

What protocols typically look at

Short flushing, mild headache, or warmth around the injection time. These fade with the compound.

First 1–2 weeks

Tolerance check at 100 mcg before stepping up. Sleep quality is the most commonly reported early marker.

Weeks 4–6

Many planning frameworks treat this as a useful checkpoint for IGF-1 labs and to decide whether to raise dose or frequency.

Weeks 8–12

Most cycles wrap up in this range, followed by 4–6 weeks off.

Per-dose (0–60 min)

Short flushing, mild headache, or warmth around the injection time. These fade with the compound.

First 1–2 weeks

Tolerance check at 100 mcg before stepping up. Sleep quality is the most commonly reported early marker.

Weeks 4–6

Many planning frameworks treat this as a useful checkpoint for IGF-1 labs and to decide whether to raise dose or frequency.

Weeks 8–12

Most cycles wrap up in this range, followed by 4–6 weeks off.

Markers are general planning references. They are not promises of an outcome.

Markers a Clinician May Track

IGF-1, often before starting and again at 4–6 weeks.

Fasting glucose and HbA1c, because GH can raise blood sugar over time.

Sleep quality, sometimes tracked with a simple journal or wearable.

Body composition, if that is the research focus, usually via consistent body-fat measurement methods.

Stopping rule

Most planning frameworks include a stopping rule: if side effects do not resolve, if IGF-1 rises far above range, or if blood sugar climbs meaningfully, the cycle is paused and reviewed with a clinician.

CJC-1295 No DAC Clinical Evidence Context

Human evidence for the No DAC variant specifically is limited. Most published human data covers the parent CJC-1295 sequence, with several Phase 1 studies and one halted Phase 2 trial.

Teichman et al. 2006 (JCEM, Phase 1)

CJC-1295 produced sustained GH and IGF-1 elevation in healthy adults with short-term tolerability data.

Ionescu and Frohman 2006 (JCEM)

Showed that pulsatile GH secretion was preserved during CJC-1295 stimulation.

Alba et al. 2006 (preclinical)

Daily CJC-1295 in GHRH-knockout mice normalized growth and body-composition markers.

Jette et al. 2005 (Endocrinology)

Identified CJC-1295 as a long-lasting GRF analog and described its albumin-binding chemistry.

ConjuChem Phase 2, 2006 (NCT00267527, DAC version)

Halted in HIV patients after a cardiac event. Investigators said the event was unrelated, but the program was discontinued. This trial used the DAC version, not No DAC.

What This Means for No DAC

No large clinical trial has been run specifically on the No DAC variant. Current dosing patterns rest on the parent CJC-1295 research above, the physiology of GHRH signaling, and the simple fact that the No DAC version uses the same receptor with a much shorter half-life. The cardiac event in the Phase 2 trial is tied to the DAC variant, not the short-acting No DAC version.

CJC-1295 No DAC Storage & Handling

Storage reference for CJC-1295 No DAC

Form

Lyophilized (powder)

Temperature

-4°F (-20°C) or below

12–24+ months

36–46°F (2–8°C)

Several months

Room temperature

Short shipping window only

Reconstituted

Reconstituted, frozen aliquots

-4°F (-20°C)

3–4 months

Lyophilized (powder)

-4°F (-20°C) or below

12–24+ months

36–46°F (2–8°C)

Several months

Room temperature

Short shipping window only

Reconstituted

Reconstituted, frozen aliquots

-4°F (-20°C)

3–4 months

Protect from light, avoid repeated freeze-thaw cycles, and discard cloudy or discolored solutions.

Use bacteriostatic water (not plain sterile water) for multi-dose vials. The benzyl alcohol keeps the solution stable for weeks in the fridge.

Store the vial upright, away from light, on a stable fridge shelf rather than the door.

If you freeze aliquots, thaw in the fridge rather than at room temperature.

CJC-1295 No DAC Protocol Mistakes & Troubleshooting

Cloudy or Discolored Vial

Discard the vial. Reconstituted CJC-1295 No DAC should be clear and colorless. Cloudiness usually means contamination or peptide degradation.

You Used the Wrong BAC Water Volume

The peptide is not ruined if the concentration differs from the chart. Recalculate the unit count using the actual volume and relabel the vial with the new concentration to avoid drawing the prior dose by mistake. The calculator can handle any vial / volume combo.

Missed Dose

Community protocols describe skipping a missed dose and resuming the schedule rather than doubling up, citing the short half-life.

Strong Flushing or Headache

Usually a sign the per-dose number is too high. Most planning frameworks step back to 100 mcg and add frequency before going higher. Effects usually fade within 30–60 minutes.

Vial Sat at Room Temperature

Short shipping windows are normal. Long room-temperature exposure after reconstitution shortens stability. If reconstituted product has been warm for more than a day or two, treat it as suspect.

Confused About Daily vs Twice-Daily

Most plans start once daily pre-bed, then add a morning fasted dose only after the single dose is tolerated. Twice daily is not required.

CJC-1295 No DAC Regulatory Status

As of June 2026, CJC-1295 No DAC (Modified GRF 1-29) is not FDA-approved. It has no active clinical development pathway tied to the No DAC variant. It sits in the same category as many other research-use peptides and is sold for research reference, not human use.

Not FDA-approved for any indication.

Not on the FDA's approved drug list as of June 2026.

Not a dietary supplement and not legal to market as one.

Banned for athletes under the World Anti-Doping Agency (WADA) S2 category.

Not interchangeable with FDA-approved GHRH analogs such as Tesamorelin (Egrifta).

Regulatory status changes from time to time. Confirm current FDA status on the FDA website before relying on any planning document.

CJC-1295 No DAC vs CJC-1295 with DAC vs Sermorelin vs Ipamorelin

CJC-1295 No DAC sits in a family of GH-